AbbVie (ABBV) Positioned for Growth With Strong Skyrizi, Rinvoq Sales, Says JPMorgan

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s second-quarter earnings report, JPMorgan reaffirmed its Overweight rating and $200 price target on AbbVie Inc. (NYSE:ABBV) on July 10.

Citing ongoing strength from Skyrizi and Rinvoq products as well as slight foreign exchange tailwinds that could result in another guidance raise, the firm expects AbbVie Inc. (NYSE:ABBV) to be well-positioned heading into the results. JPMorgan’s quarterly projections, which predict $15 billion in sales and $2.87 in earnings per share, are in line with market consensus.

According to JPMorgan, AbbVie Inc. (NYSE:ABBV) is in a solid spot as it won’t lose any significant exclusivity events until the mid-2030s, Moveover, the firm states that Skyrizi and Rinvoq can grow further, while the financial sheet has room for more business development to meet growth demands in the 2030s.

AbbVie Inc. (NYSE:ABBV) is a biopharmaceutical company that specializes in developing, manufacturing, and marketing therapies for complicated and chronic illnesses. Its next-generation immunology medications, Rinvoq and Skyrizi, continue to drive growth.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.